CN117899105A - 酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用 - Google Patents
酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用 Download PDFInfo
- Publication number
- CN117899105A CN117899105A CN202410082449.0A CN202410082449A CN117899105A CN 117899105 A CN117899105 A CN 117899105A CN 202410082449 A CN202410082449 A CN 202410082449A CN 117899105 A CN117899105 A CN 117899105A
- Authority
- CN
- China
- Prior art keywords
- soy sauce
- extraction
- dietary fiber
- sauce residue
- pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013555 soy sauce Nutrition 0.000 title claims abstract description 84
- 235000013325 dietary fiber Nutrition 0.000 title claims abstract description 51
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 43
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 23
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 23
- 241001465754 Metazoa Species 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 7
- 229940079593 drug Drugs 0.000 title description 3
- 238000000605 extraction Methods 0.000 claims abstract description 75
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 17
- 230000008859 change Effects 0.000 claims abstract description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 11
- 235000021391 short chain fatty acids Nutrition 0.000 claims abstract description 8
- 238000004458 analytical method Methods 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 239000010495 camellia oil Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 244000005709 gut microbiome Species 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 210000003608 fece Anatomy 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000193403 Clostridium Species 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 241000192125 Firmicutes Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000010871 livestock manure Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001156739 Actinobacteria <phylum> Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 3
- 241000605059 Bacteroidetes Species 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000605861 Prevotella Species 0.000 description 3
- 241000192031 Ruminococcus Species 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 241000589886 Treponema Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000927512 Barnesiella Species 0.000 description 2
- 241000372691 Candidatus Saccharibacteria Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241001464948 Coprococcus Species 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 241001137858 Euryarchaeota Species 0.000 description 2
- 241000923108 Fibrobacteres Species 0.000 description 2
- 241000662772 Flavonifractor Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 241000843248 Oscillibacter Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001180199 Planctomycetes Species 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 241000280572 Pseudoflavonifractor Species 0.000 description 2
- 241001657520 Slackia Species 0.000 description 2
- 241001180364 Spirochaetes Species 0.000 description 2
- 241000089063 Terrisporobacter Species 0.000 description 2
- 241001261005 Verrucomicrobia Species 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 2
- 235000019126 equol Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-N isocaproic acid Chemical compound CC(C)CCC(O)=O FGKJLKRYENPLQH-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241001135761 Deltaproteobacteria Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000626621 Geobacillus Species 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 241000566145 Otus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000206469 Pulsatilla Species 0.000 description 1
- 241000635201 Pumilus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001191217 Slackia isoflavoniconvertens Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0207—Control systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/028—Flow sheets
- B01D11/0284—Multistage extraction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
Abstract
本发明公开了酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,所述酱油渣膳食纤维的提取方法包括:1)取经过干燥、脱油处理的脱油酱油渣,粉碎至20‑60目;2)连续相变萃取3)将萃取釜中残渣取出,置于50‑60℃烘箱中干燥,即为酱油渣膳食纤维;并且,本发明通过动物实验证明了,酱油渣膳食纤维可以改变母猪的肠道菌群结构,促使肠道微生物群产生了更多对机体有益的短链脂肪酸,提高了肠道中的短链脂肪酸,尤其是丁酸的含量。
Description
技术领域
本发明涉及属于酱油渣资源化利用领域和保健食品技术领域,更具体地说是涉及酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用。
背景技术
酱油渣是酱醪抽油或压榨后剩下的深棕色残渣,作为酱油加工的主要副产物,每年生产约200万吨(干重),产量很大。酱油渣中存在丰富的营养成分,酱油发酵时原料中仅有蛋白质、淀粉被部分利用,酱油渣中仍含有粗蛋白、粗脂肪、膳食纤维、亲脂性维生素和黄酮类小分子活性物等营养成分。但未处理的酱油渣盐含量达10%~25%,易引起食盐中毒;且未被发酵利用的油脂中所含的大量不饱和脂肪酸极易在高水、高酸的环境中变质为过氧化脂质,有很强的细胞毒性,无法直接食用。因此对酱油渣的合理开发利用具有重要意义。
肠道炎症是兽医临床上常见的消化道疾病,多数是由大肠杆菌、沙门氏菌等引起的,在禽畜各种疾病中发病率很高,一点四季均可发病,兽医临床上对禽畜腹泻的治疗主要采用抗生素或化学药物,治疗效果不佳,且致病菌的耐药性日益显现。而针对此病症的中兽药包括止痢散、白头翁散、乌梅散等,上述中兽药一方面质量较为粗糙、用量大,另一方面生物利用度普遍较低,因此防止猪肠道炎症的效果不理想。
然而,膳食纤维能够提供多种生理健康功能,如减少餐后血糖,降低胰岛素反应;降低胆固醇水平,预防心脑血管疾病;增加饱腹感,减轻体重。同时膳食纤维能够调节肠道微生物群使其向有益的方向转变,从而调节代谢反应。哺乳动物胃肠道包含500~1000种细菌,这些微生物群的基因约是哺乳动物基因组中基因数的100倍,并可能为哺乳动物增加许多宿主缺乏的生物活性。例如,在肠道中定殖的微生物能够降解各种宿主自身无法消化分解的多糖,并提供各种代谢物,如胆汁酸、胆碱和短链脂肪酸等对宿主健康至关重要的小分子活性物。
目前,对于酱油渣膳食纤维功能活性的研究较少,更未有其对肠道炎症的作用的报道。
发明内容
有鉴于此,本发明提供了酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,动物实验研究表明,酱油渣膳食纤维可以改变母猪的肠道菌群结构,促使肠道微生物群产生了更多对机体有益的短链脂肪酸;并且,其通过将酱油渣脱油后,经粉碎干燥,以及采用中等极性溶剂进行连续相变萃取,能最大程度的保护膳食纤维中的活性成分,且提取溶剂还可回收再利用。
为了实现上述目的,本发明采用如下技术方案:
酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,所述酱油渣膳食纤维的提取方法包括以下步骤:
(1)将酱油渣在50-55℃下烘干至水分含量≤15%,然后将其粉碎至20-60目,得到酱油渣原料;
(2)将所得酱油渣原料经连续相变去油后,得到脱油酱油渣;
(3)将所得脱油酱油渣放入连续相变萃取装置中,萃取条件为:萃取剂为50-90%乙醇或乙酸乙酯,萃取温度40-60℃,连续萃取时间60-200min,萃取压力0.1-5.0Mpa,流速100-300L/h,解析温度50-95℃,解析压力为-0.1-0.5Mpa;在始终低于萃取剂的临界压力和临界温度的条件下,高压泵将萃取剂压缩为液体,以一定流速流经萃取釜萃取茶油,进入解析釜中,通过加热、减压使萃取剂相变为气体,再通过即时压缩,变为液体流经萃取釜,对物料再次萃取,如此循环多次;
(4)将萃取后的酱油渣于50-60℃下烘干至水分含量≤10%,得到酱油渣膳食纤维。
优选地,所述酱油渣膳食纤维用于调节肠道菌群失衡。
优选地,所述酱油渣膳食纤维用于提高肠道中短链脂肪酸的含量。
优选地,所述酱油渣膳食纤维用于提高肠道中丁酸的含量。
优选地,步骤(3)中,所述萃取剂为75%乙醇,萃取条件为:萃取温度60℃,萃取压力为0.5Mpa,连续萃取120min,流速100L/h,解析温度75℃,解析压力0.2Mpa。
优选地,步骤(3)中,所述萃取剂为80%乙醇,萃取条件为:萃取温度50℃,萃取压力为0.5Mpa,连续萃取100min,流速120L/h,解析温度70℃,解析压力0.2Mpa。
优选地,步骤(3)中,所述萃取剂为乙酸乙酯,萃取条件为:萃取温度55℃,萃取压力为0.5Mpa,连续萃取110min,流速100L/h,解析温度70℃,解析压力0.5Mpa。
经由上述的技术方案可知,与现有技术相比,本发明公开提供了酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,其有益效果为:
(1)本发明将含有酱油渣膳食纤维的饲料喂食的母猪作为实验组,空白对照组喂食普通饲料,分别收集两组的母猪粪便样品,通过16SrDNA测序技术研究母猪肠道菌群结构的变化,并通过GC-MS测定粪便中短链脂肪酸含量,Welch’st-test差异分析结果表明,喂食酱油渣膳食纤维后母猪肠道菌群中史雷克氏菌属(slackia)的丰度较空白对照组显著增大(p<0.05);LEfSe结果发现ClostridiumIV和δ-变形菌纲(Deltaproteobacteri)为实验组中丰度较高的两个差异物种;
(2)喂食酱油渣膳食纤维后,粪便中各短链脂肪酸含量均有不同程度的提高,尤其是丁酸含量显著增多(p<0.05);结果表明,饲料中添加酱油渣膳食纤维在一定程度上使母猪的肠道菌群结构发生改变,促进了肠道中产短链脂肪酸的菌群的富集,从而提高了肠道中的短链脂肪酸,尤其是丁酸的含量;
(3)本发明通过将脱油酱油渣粉粹、干燥;连续相变溶剂萃取去除风味物质及杂质;物料过滤并干燥即得酱油渣膳食纤维;其所采用的连续相变萃取技术是指萃取剂在低于其临界压力和临界温度条件下压缩成液体,流经萃取釜对物料进行萃取后,在解析釜中相变为气体,其中萃取得到的物质落入解析釜中,解析后的气体再经过压缩成液体,再次流经萃取釜,对物料进行反复萃取的过程,可连续多次对物料进行动态、高效萃取;
(4)与传统的溶剂、超临界萃取技术及亚临界萃取技术相比,连续相变萃取既具超临界萃取与亚临界萃取的高效、产品无溶剂残留、香气成分保留率高的优点,而且萃取压力和解析压力比超临界低,同时又具有常规溶剂萃取容积大、批处理量大、生产成本低等特点。另外,连续相变萃取还存在萃取时间短,可以实现即时连续萃取的过程,溶剂需求较少,溶剂回收等优势,且整个萃取过程在密闭绝氧、低压的条件下进行,可最大程度保留物料的活性成分。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据提供的附图获得其他的附图。
图1附图为实验组和对照组的OUT分布Venn图;
图2附图为实验组和对照组母猪肠道菌群的Alpha指数箱式图;
图3附图为实验组和对照组在属水平上的Welch’st-test丰度差异比较的误差线图;
图4附图为实验组和对照组LEfSe分析的进化分支图和柱状图;
图5附图为实验组和对照组基于OUT的PCA主成分分析图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
酱油渣膳食纤维的提取方法包括以下步骤:
(1)将酱油渣在55℃温度下烘干,使其水分含量≦15%,粉碎至60目,得到酱油渣原料;
(2)将所得酱油渣原料经连续相变去油后,得到脱油酱油渣;
(3)将所得脱油酱油渣放入连续相变萃取装置中,萃取条件为:乙醇浓度80%,萃取温度50℃,连续萃取时间100min,萃取压力0.5Mpa,流速120L/h,解析温度70℃,解析压力为0.2Mpa;在始终低于萃取剂的临界压力和临界温度的条件下,高压泵将萃取剂压缩为液体,以一定流速流经萃取釜萃取茶油,进入解析釜中,通过加热、减压使萃取剂相变为气体,再通过即时压缩,变为液体流经萃取釜,对物料再次萃取,如此循环多次;
(4)将萃取后的酱油渣于55℃温度下烘干,使其水分含量≦10%,得到酱油渣膳食纤维。
实施例2
酱油渣膳食纤维的提取方法包括以下步骤:
(1)将酱油渣在50℃温度下烘干,使其水分含量≦15%,粉碎至50目,得到酱油渣原料;
(2)将所得酱油渣原料经连续相变去油后,得到脱油酱油渣;
(3)将所得脱油酱油渣放入连续相变萃取装置中,萃取条件为:乙醇浓度75%,萃取温度60℃,连续萃取时间120min,萃取压力0.5Mpa,流速100L/h,解析温度75℃,解析压力为0.2Mpa;在始终低于萃取剂的临界压力和临界温度的条件下,高压泵将萃取剂压缩为液体,以一定流速流经萃取釜萃取茶油,进入解析釜中,通过加热、减压使萃取剂相变为气体,再通过即时压缩,变为液体流经萃取釜,对物料再次萃取,如此循环多次;
(4)将萃取后的酱油渣于55℃温度下烘干,使其水分含量≦10%,得到酱油渣膳食纤维。
试验例1
分别对实施例1-2所制得的酱油渣膳食纤维进行化学成分测定,测定结果如表1所示;
表1酱油渣膳食纤维的化学成分测定结果
试验例2酱油渣膳食纤维对母猪肠道菌群的影响
1.动物分组及饲养
选用妊娠期母猪,随机分为对照组(CK)和实验组(DF),各组3只母猪。实验组饲喂含5%酱油渣膳食纤维的饲料,对照组为不含发酵大豆膳食纤维的普通饲料,持续饲喂20d后收集各组母猪粪便,存放于-80℃冰箱中,用于分析母猪肠道菌群。
2.肠道菌群16SrDNA高通量测序分析
16Sr DNA高通量测序分析由上海生工科技有限公司完成,实验具体流程如下:样品中DNA的提取及采用琼脂糖凝胶电泳检测DNA的完整性。PCR扩增:采用细菌V3-V4区通用引物341F-805R,并引入Illumina桥式PCR兼容引物,PCR结束后进行琼脂糖凝胶电泳进行检测。将PCR扩增产物DNA纯化回收,在Illumina Miseq TM平台上上机测序。
原始测序序列经由在IlluminaMiseq TM平台上机检测后得到的原始图像数据文件经CASAVA碱基识别处理得到;后期数据处理流程为:数据处理与统计:原始序列拼接、质控过滤、去除嵌合体和非特异性扩增序列。
(1)OUT聚类;将处理后的序列根据其距离进行聚类,在97%的相似水平下将其分成OTU(operationaltaxonomicunits,操作分类单元),并制作韦恩图。
(2)Alpha多样性:Alpha多样性用于反映微生物群的丰富度和均一度,通过计算ACE、Chao、Shannon、Simpson、Coverage等指数来评价。
(3)菌群结构分析:对处理后的优质序列进行物种分类,计算各样本在不同分类水平上的序列丰度,绘制物种丰度饼图。
(4)菌群差异分析:分别采用Welch’st-test和LEfSe筛选两组样本间在各分类水平上的差异物种并做图。
(5)Beta多样性分析:各样本间的差别采用Beta多样性分析进行度量,采用主成分分析(principalcomponentanalysis,PCA)进行评价。
测定结果如下所示:
(1)OUT分类和Alpha多样性分析
如图1所示,用韦恩(Venn)图统计两组样品中共有和独有的OUT数目。CK和DF组母猪肠道菌群共有的OUT数为1491,而CK组和DF组中分别独有479个和422个OUT。喂食发酵大豆膳食纤维和喂食普通饲料的母猪相比,其肠道菌群中有小部分的细菌种类发生了改变,且细菌OUT数即物种数减少。
(2)Alpha多样性分析
各样品的Alpha多样性指数和组间的Alpha指数箱式图分别见表2和图2。DF组与CK组相比,Chao和Ace指数相对较小,而Shannon指数较大,Simpson指数较小,说明DF组的菌群多样性增大,但其丰富度减小。
表2母猪的肠道菌群Alpha多样性指数
Sample | Chao | ACE | Shannon | Simpson | Coverage |
DF-1 | 1285.69 | 1356.64 | 4.71 | 0.02 | 0.99 |
DF-2 | 1571.02 | 1648.33 | 4.45 | 0.05 | 0.99 |
DF-3 | 1545.99 | 1548.39 | 4.71 | 0.03 | 0.99 |
CK-1 | 1663.59 | 1774.66 | 4.76 | 0.02 | 0.99 |
CK-2 | 1530.69 | 1541.92 | 3.89 | 0.09 | 0.99 |
CK-3 | 1638.26 | 1981.52 | 4.12 | 0.08 | 0.99 |
(3)菌群结构分析
表3为DF和CK组菌群在主要门水平上的相对丰度及差异分析(相对丰度>0.1%)。测序得到的OUT序列分属细菌域的16个门,其中相对丰度大于0.1%的有10个门:厚壁菌门(Firmicutes)、拟杆菌门(Bacteroidetes)、变形菌门(Proteobacteria)、螺旋体菌门(Spirochaetes)、疵微菌门(Verrucomicrobia)、放线菌门(Actinobacteria)、广古菌门(Euryarchaeota)、念珠菌门(CandidatusSaccharibacteria)、浮霉菌门(Planctomycetes)和纤维杆菌门(Fibrobacteres),以及无法确定分类的细菌(unclassified)。两组间各门的相对丰度略有差异,但不存在显著性(p>0.05)。其中,在各菌门中Firmicutes丰度最高,Bacteroidetes次之,为母猪粪便肠道菌群中的优势菌门,二者丰度占总序列的90%左右,但略有浮动。
表3 DF和CK组菌群在主要门水平上的相对丰度及差异分析(%)(X±SD,n=3)
Phylum | DF | CK | p值 |
Firmicutes | 78.14±11.33 | 78.79±4.27 | 0.35 |
Bacteroidetes | 10.53±7.14 | 11.53±6.54 | 0.74 |
Proteobacteria | 3.14±0.91 | 2.70±0.82 | 0.78 |
Spirochaetes | 3.28±2.98 | 1.86±1.39 | 0.54 |
Verrucomicrobia | 1.98±2.37 | 1.85±1.11 | 0.99 |
Actinobacteria | 1.54±0.66 | 0.99±0.17 | 0.31 |
unclassified | 0.58±0.31 | 1.01±0.32 | 0.12 |
Euryarchaeota | 0.38±0.13 | 0.73±0.84 | 0.48 |
CandidatusSaccharibacteria | 0.16±0.17 | 0.35±0.05 | 0.11 |
Planctomycetes | 0.05±0.01 | 0.13±0.13 | 0.36 |
Fibrobacteres | 0.13±0.16 | 0.02±0.02 | 0.36 |
选取各组间相对丰度大于1%的各菌属进行相对丰度及差异分析如表4所示。OUT序列进行分类后分别属于153个属,DF组和CK组各有约41%和35%的序列无法确定分类(unclassified)。两组共有的主要属(相对丰度>1%)有15种,分别为Lachnospiracea_incertae_sedis、梭状芽孢杆菌XlVa属(Clostridium XIVa)、链球菌属(Streptococcus)、颤杆菌克属(Oscillibacter)、巴恩斯氏菌属(Barnesiella)、密螺旋体菌属(Treponema)、Pseudoflavonif ractor、大肠杆菌/志贺菌属(Escherichia/Shigella)、梭状芽孢杆菌属(Clostridiumsensustricto)、瘤胃球菌属(Ruminococcus)、Subdivision5_genera_incertae_sedis、土孢杆菌属(Terrisporobacter))和Flavonifractor。另外DF组中梭状芽孢杆菌IV属(Clostridium IV)、普雷沃氏菌属(Prevotella)和粪球菌属(Coprococcus)的相对丰度均大于1%,但在CK组中相对丰度小于1%;乳酸杆菌属(Lactobacillus)在CK组肠道细菌中相对丰度占1.09%,DF组中仅占0.99%。
在属水平上,各样本的肠道细菌约有27.86~47.73%的序列无法确定分类,占比最大。其次相对丰度较大的依次为Lachnospiracea_incertae_sedis、Clostr idiumXlVa和Streptococcus,三者均为Firmicutes中菌属;Clostridium中包含有潜在的益生菌,ClostridiumXIVa、ClostridiumIV中的部分芽孢杆菌菌株已被报道可减轻炎症及过敏性疾病。
表4 DF和CK组菌群在主要属水平上的相对丰度及差异分析(%)(X±SD,n=3)
Genus | DF | CK | P值 |
unclassified | 40.81±8.68 | 34.54±7.55 | 0.43 |
Lachnospiracea_incertae_sedis | 11.95±8.39 | 21.91±10.33 | 0.23 |
ClostridiumXIVa | 8.56±2.42 | 8.02±0.62 | 0.80 |
Streptococcus | 4.11±3.47 | 5.20±3.44 | 0.79 |
Oscillibacter | 3.06±0.92 | 2.59±0.66 | 0.62 |
Barnesiella | 1.75±2.00 | 3.34±3.86 | 0.62 |
Treponema | 3.22±2.92 | 1.81±1.29 | 0.50 |
Pseudoflavonifractor | 2.62±2.04 | 2.23±1.17 | 0.81 |
Escherichia/Shigella | 2.20±0.83 | 2.14±0.78 | 0.93 |
Clostridiumsensustricto | 1.53±0.46 | 2.16±0.67 | 0.16 |
Ruminococcus | 1.25±0.48 | 2.26±2.96 | 0.63 |
Subdivision5_genera_incertae_sedis | 1.76±2.27 | 1.77±1.01 | 0.96 |
Terrisporobacter | 1.41±0.29 | 1.65±0.63 | 0.60 |
ClostridiumIV | 1.72±0.71 | 0.96±0.13 | 0.15 |
Flavonifractor | 1.05±0.69 | 1.36±0.93 | 0.65 |
Prevotella | 1.36±0.52 | 0.78±0.16 | 0.22 |
Lactobacillus | 0.99±0.90 | 1.09±0.94 | 0.94 |
Coprococcus | 1.66±1.85 | 0.35±0.39 | 0.35 |
(4)菌群差异分析
分别采用Welch’st-test和LEfSe进行组间物种差异分析。
图3为在属水平上两组间进行Welch’st-test丰度差异比较的误差线图。在属水平上,DF组slackia丰度显著高于CK组(p<0.05),但其在DF组中的相对丰度仅占0.01%,为Actinobacteria中的一个菌属;其中部分菌株如Slackia isoflavoniconvertens为人类粪便中分离出的少数具有形成雌马酚特征的菌株,其代谢底物为大豆异黄酮的两种苷元形式——大豆苷元和染料木素,并将其转化为雌马酚和5-羟基雌马酚。
图4为LEfSe分析的进化分支图和柱状图。与CK组相比,DF组中丰度较高的物种有:ClostridiumIV和δ-变形菌纲(Deltaproteobacteria)。
(5)Beta多样性分析
图5为所有样本基于OUT的PCA图,并选取了能够最大程度反映样品间差异的两个坐标轴(即PC1和PC2),第一主成分贡献77%,第二主成分贡献为10%,二者共贡献87%。图中黄色代表DF组,蓝色代表CK组,各点间的距离代表样本间肠道菌群的结构差异。DF组的各样本分布较集中,而CK组的各样本间距较分散。
结果表明,将5%母猪饲料替换为发酵大豆膳食纤维后,母猪的肠道菌群结构发生一定程度趋向性的变化。CK组的各样本聚类较分散,可能是喂食普通饲料的个体自身健康状况、年龄等其他因素造成的。
试验例3短链脂肪酸含量测定
取500mg粪便于5mL研磨离心管中,加入1.0mL 1%磷酸溶液,放入同等体积的1mm研磨珠,在珠磨机中研磨2min。观察研磨彻底后加入1mL乙酸乙酯,用vortex涡旋振荡,使体系充分混匀。离心取上层有机试剂层于-20℃冰箱备用。上机分析前,加入4-甲基戊酸作为内标,用于纠正每次注射样品量间的变化和仪器响应的微小变化。每个样品进行3次独立重复提取实验,测定结果如表5所示。
气相色谱采用极性毛细管柱DB-WAX,氦气载气浓度1mL/min,质谱检测器扫描范在30~250m/z之间,离子源、四极杆和界面温度分别为230℃、150℃和280℃。采用分流模式,设置分流比为50:1,进样量5μL,进样口温度250℃。跑样时柱温起始温度90℃跑3min,然后15℃/min升温至150℃,150℃下维持3min,最后2℃/min升温至160℃并在此温度下维持2min。总运行时间为17min。
表5 CK和DF组母猪粪便中的SCFAs含量(X±SE,n=3)
由表5可知,除丁酸外的其他短链脂肪酸含量在DF组中均有增加,但差异并不显著(p>0.05);仅丁酸含量在DF组中显著增加(p<0.05)。对在粪便中得到的短链脂肪酸含量,其说明含义是有限的,该结果无法表征结肠近端发酵和短链脂肪酸吸收的动态过程,但对于肠道远端的短链脂肪酸含量有一定的代表性。
在肠道末端,肠道菌群发酵膳食纤维产生的短链脂肪酸可以通过扩散或转运进入细胞,并作为胃肠道细胞的重要能量来源,调节免疫反应及维持黏膜稳态。其中乙酸和丙酸影响饱腹感和肠道转运,并能通过循环系统直接影响脂肪组织、大脑和肝脏,特别是丙酸盐能被肝细胞利用进行糖异生转化为葡萄糖。而丁酸可诱导粘蛋白合成,使上皮细胞之间的连接收紧,并抑制组蛋白脱乙酰基酶类的活性,从而防止肠道炎症和肠漏综合征,预防结肠癌。此外,拟杆菌门中某些细菌如拟杆菌属会将乳酸转化为其他短链脂肪酸如乙酸、甲酸或丙酸,这些脂肪酸的大量堆积会损害肠道内壁。
DF组中丁酸含量的显著提高说明发酵大豆膳食纤维可促进丁酸的产生,保护肠道内壁并预防肠道炎症和结肠癌。
本说明书中各个实施例采用递进的方式描述,每个实施例重点说明的都是与其他实施例的不同之处,各个实施例之间相同相似部分互相参见即可。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (7)
1.酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,其特征在于,所述酱油渣膳食纤维的提取方法包括以下步骤:
(1)将酱油渣在50-55℃下烘干至水分含量≤15%,然后将其粉碎至20-60目,得到酱油渣原料;
(2)将所得酱油渣原料经连续相变去油后,得到脱油酱油渣;
(3)将所得脱油酱油渣放入连续相变萃取装置中,萃取条件为:萃取剂为50-90%乙醇或乙酸乙酯,萃取温度40-60℃,连续萃取时间60-200min,萃取压力0.1-5.0Mpa,流速100-300L/h,解析温度50-95℃,解析压力为-0.1-0.5Mpa;在始终低于萃取剂的临界压力和临界温度的条件下,高压泵将萃取剂压缩为液体,以一定流速流经萃取釜萃取茶油,进入解析釜中,通过加热、减压使萃取剂相变为气体,再通过即时压缩,变为液体流经萃取釜,对物料再次萃取,如此循环多次;
(4)将萃取后的酱油渣于50-60℃下烘干至水分含量≤10%,得到酱油渣膳食纤维。
2.根据权利要求1所述的酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,其特征在于,所述酱油渣膳食纤维用于调节肠道菌群失衡。
3.根据权利要求1所述的酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,其特征在于,所述酱油渣膳食纤维用于提高肠道中短链脂肪酸的含量。
4.根据权利要求1所述的酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,其特征在于,所述酱油渣膳食纤维用于提高肠道中丁酸的含量。
5.根据权利要求1所述的酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,其特征在于,步骤(3)中,所述萃取剂为75%乙醇,萃取条件为:萃取温度60℃,萃取压力为0.5Mpa,连续萃取120min,流速100L/h,解析温度75℃,解析压力0.2Mpa。
6.根据权利要求1所述的酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,其特征在于,步骤(3)中,所述萃取剂为80%乙醇,萃取条件为:萃取温度50℃,萃取压力为0.5Mpa,连续萃取100min,流速120L/h,解析温度70℃,解析压力0.2Mpa。
7.根据权利要求1所述的酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用,其特征在于,步骤(3)中,所述萃取剂为乙酸乙酯,萃取条件为:萃取温度55℃,萃取压力为0.5Mpa,连续萃取110min,流速100L/h,解析温度70℃,解析压力0.5Mpa。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410082449.0A CN117899105A (zh) | 2021-06-22 | 2021-06-22 | 酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110693660.2A CN113615808A (zh) | 2021-06-22 | 2021-06-22 | 一种酱油渣来源的发酵大豆膳食纤维的制备方法及其应用 |
CN202410082449.0A CN117899105A (zh) | 2021-06-22 | 2021-06-22 | 酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110693660.2A Division CN113615808A (zh) | 2021-06-22 | 2021-06-22 | 一种酱油渣来源的发酵大豆膳食纤维的制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117899105A true CN117899105A (zh) | 2024-04-19 |
Family
ID=78378238
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410082449.0A Pending CN117899105A (zh) | 2021-06-22 | 2021-06-22 | 酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用 |
CN202110693660.2A Pending CN113615808A (zh) | 2021-06-22 | 2021-06-22 | 一种酱油渣来源的发酵大豆膳食纤维的制备方法及其应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110693660.2A Pending CN113615808A (zh) | 2021-06-22 | 2021-06-22 | 一种酱油渣来源的发酵大豆膳食纤维的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN117899105A (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114657230B (zh) * | 2022-02-23 | 2023-11-24 | 中国农业科学院北京畜牧兽医研究所 | 一种仿生消化联合体外发酵评估纤维原料发酵特性的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103173280B (zh) * | 2013-03-06 | 2015-03-18 | 曹庸 | 一种连续相变萃取酱油渣油脂的方法 |
CN103173279A (zh) * | 2013-03-06 | 2013-06-26 | 曹庸 | 一种连续相变萃取茶油的方法 |
CN110025015A (zh) * | 2019-04-15 | 2019-07-19 | 江苏师范大学 | 甘薯渣膳食纤维的提取方法及其在调节肠道菌群中的应用 |
CN111513190A (zh) * | 2020-05-08 | 2020-08-11 | 山东理工大学 | 一种酱油渣发酵方法、发酵方法制得的饲料和饲料的应用 |
-
2021
- 2021-06-22 CN CN202410082449.0A patent/CN117899105A/zh active Pending
- 2021-06-22 CN CN202110693660.2A patent/CN113615808A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113615808A (zh) | 2021-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fu et al. | Cistanche polysaccharides enhance echinacoside absorption in vivo and affect the gut microbiota | |
Zhou et al. | Fermented soybean dregs by neurospora crassa: A traditional prebiotic food | |
Tian et al. | Moringa oleifera polysaccharides regulates caecal microbiota and small intestinal metabolic profile in C57BL/6 mice | |
Li et al. | Effects of in vitro digestion and fermentation of Nostoc commune Vauch. polysaccharides on properties and gut microbiota | |
CN111647091B (zh) | 一种太子参活性六碳醛低聚糖及其制备方法与应用 | |
Xie et al. | Dietary polysaccharide from Mung bean [Vigna radiate (Linn.) Wilczek] skin modulates gut microbiota and short‐chain fatty acids in mice | |
CN114832022B (zh) | 一种桑黄子实体酚类活性物质的制备及其在调节肠道菌群、尿酸代谢中的应用 | |
Wang et al. | Effect of two-week red beetroot juice consumption on modulation of gut microbiota in healthy human volunteers–a pilot study | |
CN117899105A (zh) | 酱油渣膳食纤维在制备预防或治疗动物肠道炎症药物中的应用 | |
Ma et al. | Enzymatic-modified dietary fibre fraction extracted from potato residue regulates the gut microbiotas and production of short-chain fatty acids of C57BL/6 mice | |
Yi et al. | In vitro digestion, fecal fermentation, and gut bacteria regulation of brown rice gel prepared from rice slurry backfilled with rice bran | |
Wang et al. | Peanut by-products utilization technology | |
Wang et al. | Anti‐diabetic effect of banana peel dietary fibers on type 2 diabetic mellitus mice induced by streptozotocin and high‐sugar and high‐fat diet | |
Aljumaah et al. | Influence of sanguinarine-based phytobiotic supplementation on post necrotic enteritis challenge recovery | |
Yue et al. | Effects of monoglucoside and diglucoside anthocyanins from Yan 73 (Vitis vinifera L.) and spine grape (Vitis davidii Foex) skin on intestinal microbiota in vitro | |
CN109688832B (zh) | 家畜用饲料或家畜用补充剂、乳杆菌属细菌的生长促进剂以及乳杆菌属细菌的生长促进方法 | |
Ha et al. | Supplemental protease improves in vitro disappearance of dry matter and crude protein in feather meal and copra meal for pigs | |
Yang et al. | Fermentation of dietary fibers modified by an enzymatic‐ultrasonic treatment and evaluation of their impact on gut microbiota in mice | |
Cao et al. | Positive effects of dietary fiber from sweet potato [Ipomoea batatas (L.) Lam.] peels by different extraction methods on human fecal microbiota in vitro fermentation | |
Daştan et al. | Sex-dependent colonic microbiota modulation by hazelnut (Corylus avellana L.) dietary fiber | |
Du et al. | Soybean oligosaccharides combined with probiotics reduce faecal odour compound content by improving intestinal microbiota in pigs | |
CN114057905B (zh) | 一种蒸制黄精多糖及其在调整肠道微生物中的应用 | |
Dakheel et al. | Use of tannin-containing plants as antimicrobials influencing the animal health | |
Huang et al. | Effects of dietary supplementation with Ampelopsis grossedentata extract on production performance and body health of hens | |
CN109758485A (zh) | 红菇提取物在制备治疗和/或预防肠道菌群失调症及相关疾病的制剂中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |